{"@context":{"@vocab":"https://schema.org/"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/fda/warning-letters/recent","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://creativecommons.org/publicdomain/zero/1.0/","primary_source":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters","generated_at":"2026-10-05T09:55:47.226Z"},"count":26,"filters":{"office":"Office of Pharmaceutical Quality"},"items":[{"id":"b12228329f6fef09","posted_date":"2024-09-17","letter_issue_date":"2024-08-12","company_name":"Greco Gas, Inc.","issuing_office":"Office of Pharmaceutical Quality","subject":"CGMP/Finished Pharmaceuticals/Adulterated","canonical_url":"https://api.morvs.ai/fda-warning/b12228329f6fef09"},{"id":"2727c21ca7e7efb1","posted_date":"2024-08-27","letter_issue_date":"2024-07-12","company_name":"EyePoint Pharmaceuticals, Inc.","issuing_office":"Office of Pharmaceutical Quality Operations Division I","subject":"CGMP/Drugs/Adulterated","canonical_url":"https://api.morvs.ai/fda-warning/2727c21ca7e7efb1"},{"id":"171f77dcd54ced46","posted_date":"2024-07-16","letter_issue_date":"2024-06-20","company_name":"Max Chemical Inc.","issuing_office":"Office of Pharmaceutical Quality Operations, Division II","subject":"CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated","canonical_url":"https://api.morvs.ai/fda-warning/171f77dcd54ced46"},{"id":"5d82eff6012ebf92","posted_date":"2024-07-16","letter_issue_date":"2024-06-11","company_name":"ARG Laboratories, Inc.","issuing_office":"Office of Pharmaceutical Quality Operations, Division II","subject":"CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated","canonical_url":"https://api.morvs.ai/fda-warning/5d82eff6012ebf92"},{"id":"a77bd291127973c7","posted_date":"2024-01-09","letter_issue_date":"2023-09-13","company_name":"Curexa – East, LLC dba Curexa","issuing_office":"Office of Pharmaceutical Quality","subject":"Compounding Pharmacy/Adulterated Drug Products","canonical_url":"https://api.morvs.ai/fda-warning/a77bd291127973c7"},{"id":"b78c1be4bd7d4d4c","posted_date":"2024-01-09","letter_issue_date":"2024-01-02","company_name":"Prime Lab LLC","issuing_office":"Office of Pharmaceutical Quality","subject":"CGMP/Finished Pharmaceuticals/Adulterated","canonical_url":"https://api.morvs.ai/fda-warning/b78c1be4bd7d4d4c"},{"id":"a0a667d1fd356895","posted_date":"2023-12-26","letter_issue_date":"2023-12-12","company_name":"Omeza LLC","issuing_office":"Office of Pharmaceutical Quality","subject":"CGMP/Finished Pharmaceuticals/Adulterated","canonical_url":"https://api.morvs.ai/fda-warning/a0a667d1fd356895"},{"id":"f6b01f4aa30f748e","posted_date":"2023-11-21","letter_issue_date":"2023-11-08","company_name":"National Chemical Laboratories","issuing_office":"Office of Pharmaceutical Quality Operations","subject":"CGMP/Finished Pharmaceuticals/Adulterated","canonical_url":"https://api.morvs.ai/fda-warning/f6b01f4aa30f748e"},{"id":"40bebb9f18c8439f","posted_date":"2023-01-31","letter_issue_date":"2023-01-27","company_name":"Kobayashi Healthcare International, Inc.","issuing_office":"Office of Pharmaceutical Quality","subject":"CGMP/Finished Pharmaceuticals/Adulterated","canonical_url":"https://api.morvs.ai/fda-warning/40bebb9f18c8439f"},{"id":"cc6e0da3033ae548","posted_date":"2022-09-13","letter_issue_date":"2022-09-02","company_name":"Sanitizer Supply LLC","issuing_office":"Office of Pharmaceutical Quality Operations, Division II","subject":"CGMP/Finished Pharmaceuticals/Adulterated","canonical_url":"https://api.morvs.ai/fda-warning/cc6e0da3033ae548"},{"id":"683be256f35e1a43","posted_date":"2022-09-13","letter_issue_date":"2022-08-29","company_name":"Vita Pharmacy, LLC dba Talon Pharmacy of Boerne","issuing_office":"Office of Pharmaceutical Quality Operations, Division II","subject":"Compounding Pharmacy/Adulterated Drug Products","canonical_url":"https://api.morvs.ai/fda-warning/683be256f35e1a43"},{"id":"7a3f222f490bf2a7","posted_date":"2022-06-28","letter_issue_date":"2022-06-10","company_name":"Monarch PCM, LLC","issuing_office":"Office of Pharmaceutical Quality Operations, Division II","subject":"CGMP/Finished Pharmaceuticals/Adulterated","canonical_url":"https://api.morvs.ai/fda-warning/7a3f222f490bf2a7"},{"id":"0cb6cd9f6886beff","posted_date":"2022-06-14","letter_issue_date":"2022-06-07","company_name":"Hybrid Pharma, LLC","issuing_office":"Office of Pharmaceutical Quality Operations, Division II","subject":"Compounding Pharmacy/Adulterated Drug Products","canonical_url":"https://api.morvs.ai/fda-warning/0cb6cd9f6886beff"},{"id":"cdd003798242fe98","posted_date":"2022-02-08","letter_issue_date":"2022-01-26","company_name":"Innoveix Pharmaceuticals Inc","issuing_office":"Office of Pharmaceutical Quality Operations, Division II","subject":"Compounding Pharmacy/Adulterated Drug Products","canonical_url":"https://api.morvs.ai/fda-warning/cdd003798242fe98"},{"id":"d901f2b594d34e50","posted_date":"2022-01-18","letter_issue_date":"2021-09-20","company_name":"Apothecary Health Solutions/Right Value Drug Stores, LLC dba Carie Boyd's Prescription Shop","issuing_office":"Office of Pharmaceutical Quality Operations, Division II","subject":"Compounding Pharmacy/Adulterated Drug Products","canonical_url":"https://api.morvs.ai/fda-warning/d901f2b594d34e50"},{"id":"ff50be88f5a93e09","posted_date":"2021-11-16","letter_issue_date":"2021-07-22","company_name":"Matthew 7:25 Inc dba Thrive Pharmacy","issuing_office":"Office of Pharmaceutical Quality Operations, Division II","subject":"Compounding Pharmacy/Adulterated Drug Products","canonical_url":"https://api.morvs.ai/fda-warning/ff50be88f5a93e09"},{"id":"086aa900ec5be752","posted_date":"2021-10-26","letter_issue_date":"2021-10-15","company_name":"Empower Clinic Services, LLC dba Empower Pharmacy","issuing_office":"Office of Pharmaceutical Quality Operations, Division II","subject":"Compounding Pharmacy/Adulterated Drug Products","canonical_url":"https://api.morvs.ai/fda-warning/086aa900ec5be752"},{"id":"e8bde50bee02a440","posted_date":"2021-10-19","letter_issue_date":"2021-09-21","company_name":"Sircle Laboratories, LLC","issuing_office":"Office of Pharmaceutical Quality Operations, Division II","subject":"CGMP/Finished Pharmaceuticals/Adulterated","canonical_url":"https://api.morvs.ai/fda-warning/e8bde50bee02a440"},{"id":"80cfaa8f81cad159","posted_date":"2021-10-05","letter_issue_date":"2021-09-17","company_name":"Walfer Corporation dba The Medicine Shoppe Pharmacy","issuing_office":"Office of Pharmaceutical Quality Operations, Division II","subject":"Compounding Pharmacy/Adulterated Drug Products","canonical_url":"https://api.morvs.ai/fda-warning/80cfaa8f81cad159"},{"id":"896ef37c4c368149","posted_date":"2021-09-07","letter_issue_date":"2021-08-06","company_name":"Genesis Nutrition Ultra Slim dba Genesis Ultra Slim","issuing_office":"Office of Pharmaceutical Quality Operations, Division II","subject":"Unapproved New Drugs/Misbranded","canonical_url":"https://api.morvs.ai/fda-warning/896ef37c4c368149"},{"id":"7a2f8329d2e8e90d","posted_date":"2021-08-17","letter_issue_date":"2021-08-06","company_name":"Maitland Labs of Central Florida","issuing_office":"Office of Pharmaceutical Quality Operations, Division II","subject":"Compounding Pharmacy/Adulterated Drug Products","canonical_url":"https://api.morvs.ai/fda-warning/7a2f8329d2e8e90d"},{"id":"a42707859c44c85b","posted_date":"2021-08-10","letter_issue_date":"2021-07-27","company_name":"Sanit Technologies, LLC dba Durisan","issuing_office":"Office of Pharmaceutical Quality Operations, Division II","subject":"CGMP/Finished Pharmaceuticals/Adulterated","canonical_url":"https://api.morvs.ai/fda-warning/a42707859c44c85b"},{"id":"d66f4c27b31d96d1","posted_date":"2021-08-03","letter_issue_date":"2021-07-29","company_name":"Farmakeio Outsourcing LLC","issuing_office":"Office of Pharmaceutical Quality Operations, Division II","subject":"Compounding Pharmacy/Adulterated Drug Products","canonical_url":"https://api.morvs.ai/fda-warning/d66f4c27b31d96d1"},{"id":"c8b816c367203ac7","posted_date":"2021-08-03","letter_issue_date":"2021-07-06","company_name":"Syntec Pharma Corp","issuing_office":"Office of Pharmaceutical Quality Operations Division I","subject":"CGMP/Active Pharmaceutical Ingredient (API)/Adulterated","canonical_url":"https://api.morvs.ai/fda-warning/c8b816c367203ac7"},{"id":"0224fa71fc24120f","posted_date":"2021-04-27","letter_issue_date":"2021-04-05","company_name":"American Specialty Pharmacy, Inc. dba ASP Cares","issuing_office":"Office of Pharmaceutical Quality Operations, Division II","subject":"Compounding Pharmacy/Adulterated Drug Products","canonical_url":"https://api.morvs.ai/fda-warning/0224fa71fc24120f"},{"id":"2331cfaf31aabf04","posted_date":"2021-04-27","letter_issue_date":"2021-04-08","company_name":"Exela Pharma Sciences LLC","issuing_office":"Office of Pharmaceutical Quality Operations, Division II","subject":"Unapproved New Drug/Compounding/Misbranding","canonical_url":"https://api.morvs.ai/fda-warning/2331cfaf31aabf04"}]}